Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Historical CYCN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Slingshot Bullish | Bullish Swing Setup | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Wide Range Bar | Range Expansion | -13.83% | |
| Upper Bollinger Band Walk | Strength | -13.83% | |
| Wide Bands | Range Expansion | -13.83% | |
| Above Upper BB | Strength | -13.83% | |
| Upper Bollinger Band Touch | Strength | -13.83% | |
| Expansion Breakout | Bullish Swing Setup | -21.06% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Medicine Biopharmaceutical Medical Specialties Diseases Organ Systems Heart Failure Kidney Diseases Diabetic Nephropathy Sickle Cell Disease Cardiomyopathy
Medicine Biopharmaceutical Medical Specialties Diseases Organ Systems Heart Failure Kidney Diseases Diabetic Nephropathy Sickle Cell Disease Cardiomyopathy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.0 |
| 52 Week Low | 1.69 |
| Average Volume | 812,594 |
| 200-Day Moving Average | 7.94 |
| 50-Day Moving Average | 3.26 |
| 20-Day Moving Average | 4.01 |
| 10-Day Moving Average | 4.42 |
| Average True Range | 0.52 |
| ADX | 33.49 |
| +DI | 39.55 |
| -DI | 16.41 |
| Chandelier Exit (Long, 3 ATRs ) | 4.68 |
| Chandelier Exit (Short, 3 ATRs ) | 4.71 |
| Upper Bollinger Band | 5.30 |
| Lower Bollinger Band | 2.72 |
| Percent B (%b) | 0.73 |
| BandWidth | 64.20 |
| MACD Line | 0.44 |
| MACD Signal Line | 0.34 |
| MACD Histogram | 0.0965 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.77 | ||||
| Resistance 3 (R3) | 5.87 | 5.60 | 5.57 | ||
| Resistance 2 (R2) | 5.60 | 5.30 | 5.54 | 5.51 | |
| Resistance 1 (R1) | 5.10 | 5.12 | 4.97 | 5.00 | 5.44 |
| Pivot Point | 4.83 | 4.83 | 4.76 | 4.77 | 4.83 |
| Support 1 (S1) | 4.33 | 4.53 | 4.20 | 4.23 | 3.78 |
| Support 2 (S2) | 4.06 | 4.35 | 4.00 | 3.71 | |
| Support 3 (S3) | 3.56 | 4.06 | 3.65 | ||
| Support 4 (S4) | 3.46 |
